

Alping, P., et al. (2021). Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis. *Neurology*, 96(11), e1574–e1584. <https://doi.org/10.1212/wnl.0000000000011545>

Boffa, G., et al. (2020). Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab. *European Journal of Neurology*, 27(10), 2047–2055. <https://doi.org/10.1111/ene.14324>

Boffa, G., et al. (2021). Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. *Neurology*, 96(8), e1215–e1226. <https://doi.org/10.1212/wnl.0000000000011461>

Boffa, G., et al. (2020). Autologous hematopoietic stem cell transplantation following alemtuzumab therapy in aggressive multiple sclerosis: A report of three cases. *Multiple Sclerosis Journal*, 135245852091481. <https://doi.org/10.1177/1352458520914818>

Cohen, J. A., et al. (2019). Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. *Biology of Blood and Marrow Transplantation*, 25(5), 845–854. <https://doi.org/10.1016/j.bbmt.2019.02.014>

Kvistad, S. A. S., et al. (2019). Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway. *Multiple Sclerosis Journal*, 26(14), 1889–1897. <https://doi.org/10.1177/1352458519893926>

Sharrack, B., et al. (2019). Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). *Bone Marrow Transplantation*, 55(2), 283–306. <https://doi.org/10.1038/s41409-019-0684-0>

Zhukovsky, C., et al. (2020). Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study. *Journal of Neurology, Neurosurgery & Psychiatry*, 92(2), 189–194. <https://doi.org/10.1136/jnnp-2020-323992>